Lepu Medical has signed a strategic cooperation agreement with Intel: Launching a new era of artificial intelligence application on healthcare.
On May 15. 2019, an Intel Medical AI Forum was hosted at the 81st China International Medical Equipment Fair (CMEF). Internationally renowned Al application experts, medical device and information specialists, top management of medical device manufacturers attended the forum and shared their views on the rise of artificial intelligence...
On November 19, 2018, Shenzhen Carewell Electronics Co., Ltd., a subsidiary of Lepu Medical, announced that its product AI-ECG Platform, an artificial intelligence (AI) automatic analysis and diagnosis system for ECG, was cleared in the US Food and Drug Administration (FDA).AI-ECG Platform is the first Chinese innovative medical device in the AI ECG field with FDA clearance.
On December 1, 2018, the 2nd Cross-Strait Smart ECG Man-Machine Contest was successfully held by DrKing Medicine (DrKing Platform) in the process of the 9th Cross-Strait Cardiovascular Disease Summit Forum.
In recent years, “artificial intelligence” has become one of the key words of technological development all over the world, and it appears more and more frequently in people's daily life. On October 14, 2018, many cardiologists and specialists from domestic and foreign pharmaceutical enterprises gathered at the 29th Great Wall International Congress of Cardiology (GW-ICC) “Industry-University-Research” Joint Session, to present and discuss on the latest research findings and hot topics in the field.
The thriving artificial intelligence (AI) technology is altering the way how we live and work, and healthcare is the major field on which AI research focuses. On March 24, 2018, Lepu Medical has launched its in-house AI-ECG Platform, an automatic ECG analysis & diagnosis system, in the 16th China Interventional Therapeutics (CIT). The launching testifies that Lepu has stepped close towards the comprehensive AI layout and development on healthcare.